Vertex Pharmaceuticals Risk Analysis And Volatility

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Macroaxis considers Vertex Pharmaceuticals very steady given 3 months investment horizon. Vertex Pharmaceuticals owns Efficiency Ratio (i.e. Sharpe Ratio) of 0.1955 which indicates the firm had 0.1955% of return per unit of risk over the last 3 months. Our philosophy towards measuring volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Vertex Pharmaceuticals Incorpor which you can use to evaluate future volatility of the company. Please operate Vertex Pharmaceuticals Risk Adjusted Performance of 0.1236, Coefficient Of Variation of 603.59 and Semi Deviation of 1.1 to confirm if our risk estimates are consistent with your expectations.
Interest Expense

90 Days Market Risk

Very steady

Chance of Distress in 24 months

Very low

90 Days Economic Sensitivity

Follows market closely
Horizon     30 Days    Login   to change

Vertex Pharmaceuticals Market Sensitivity

As returns on market increase, Vertex Pharmaceuticals returns are expected to increase less than the market. However during bear market, the loss on holding Vertex Pharmaceuticals will be expected to be smaller as well.
3 Months Beta |Analyze Vertex Pharmaceuticals Demand Trend
Check current 30 days Vertex Pharmaceuticals correlation with market (DOW)
β = 0.7427

Vertex Pharmaceuticals Central Daily Price Deviation

Vertex Pharmaceuticals Technical Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Developed by Larry Williams, the Weighted Close is the average of Vertex Pharmaceuticals high, low and close of a chart with the close values weighted twice. It can be used to smooth an indicator that normally takes only Vertex Pharmaceuticals closing price as input. View also all equity analysis or get more info about weighted close price price transform indicator.

Vertex Pharmaceuticals Projected Return Density Against Market

Given the investment horizon of 30 days, Vertex Pharmaceuticals has beta of 0.7427 . This entails as returns on market go up, Vertex Pharmaceuticals average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Vertex Pharmaceuticals Incorpor will be expected to be much smaller as well. Moreover, The company has an alpha of 0.1679 implying that it can potentially generate 0.1679% excess return over DOW after adjusting for the inherited market risk (beta).
 Predicted Return Density 
      Returns 
Given the investment horizon of 30 days, the coefficient of variation of Vertex Pharmaceuticals is 511.57. The daily returns are destributed with a variance of 2.24 and standard deviation of 1.5. The mean deviation of Vertex Pharmaceuticals Incorpor is currently at 1.2. For similar time horizon, the selected benchmark (DOW) has volatility of 0.71
α
Alpha over DOW
=0.17
β
Beta against DOW=0.74
σ
Overall volatility
=1.50
Ir
Information ratio =0.09

Vertex Pharmaceuticals Return Volatility

the company inherits 1.4953% risk (volatility on return distribution) over the 30 days horizon. the entity inherits 0.651% risk (volatility on return distribution) over the 30 days horizon.
 Performance (%) 
      Timeline 

Vertex Pharmaceuticals Investment Opportunity

Vertex Pharmaceuticals Incorpor has a volatility of 1.5 and is 2.31 times more volatile than DOW. 13  of all equities and portfolios are less risky than Vertex Pharmaceuticals. Compared to the overall equity markets, volatility of historical daily returns of Vertex Pharmaceuticals Incorpor is lower than 13 () of all global equities and portfolios over the last 30 days. Use Vertex Pharmaceuticals Incorpor to protect your portfolios against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of Vertex Pharmaceuticals to be traded at $201.6 in 30 days. . As returns on market increase, Vertex Pharmaceuticals returns are expected to increase less than the market. However during bear market, the loss on holding Vertex Pharmaceuticals will be expected to be smaller as well.

Vertex Pharmaceuticals correlation with market

correlation synergy
Weak diversification
Overlapping area represents the amount of risk that can be diversified away by holding Vertex Pharmaceuticals Incorpo and equity matching DJI index in the same portfolio.

Vertex Pharmaceuticals Current Risk Indicators

Vertex Pharmaceuticals Suggested Diversification Pairs

Also please take a look at World Market Map. Please also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Search macroaxis.com